On November 15, 2018, within the framework of a regular meeting of the Sverdlovsk Association of Endocrinologists, the results of clinical trials of Rosinsulin M Mix 30/70, 2-phase genetically engineered human insulin, were presented in Rymar Oksana's report “Basic clinical and laboratory parameters in patients with type 2 diabetes mellitus amid the therapy of combined domestic insulins and metformins in the real-world clinical practice."

The goal of the study was to evaluate carbohydrate metabolism amid using two-phase human genetically engineered insulin (Rosinsulin M mix 30/70) in patients with type 2 diabetes who have not previously received insulin therapy and have not achieved target carbohydrate metabolism levels after taking oral glucose-lowering drugs. The study involved 36 patients with type 2 diabetes mellitus (11 men and 25 women) who received a combination of metformin and sulfonylurea in the highest tolerated doses and did not reach target carbohydrate metabolism figures. The results showed that Rosinsulin M mix 30/70 in combination with metformin had a pronounced sugar-lowering effect in patients with poor glycemic control amid the previous combination therapy with metformin and sulfonylurea.